Summary and Concluding Remarks
Dr Carrié ended the symposium by stating that there remains an unmet need for clinical data demonstrating the value of new generation DES, particularly in terms of long-term outcomes and in patients with diabetes. The NEXT clinical study has proven high Cre8 efficacy in diabetics. Ongoing clinical studies such as Investig8 and the TLVMC Cre8™ study have confirmed the efficacy of the device in all comers patients with a high proportion of diabetic patients (35 % and 38 % respectively). Ongoing evaluations will provide further evidence in this challenging setting. The Demonstr8 randomised trial has provided evidence in support of the excellent safety profile of the device, showing almost complete Cre8 strut coverage at three months. Single-centre experiences have suggested that Cre8 may enable a shorter duration of DAPT following stent implantation, although further studies are needed to confirm this finding. In conclusion, the unique features of the Cre8™ stent have provided high efficacy and safety in challenging clinical settings.
The publication of the article was supported by Alvimedica.